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Neonatal administration of estradiol-1 7,B (E2-17f) increases the nuclear DNA content in the mouse
reproductive tract. Similar responses have been demonstrated for synthetic estrogens such as
diethylstilbestrol. One of the questions raised regarding environmental estrogens such as
organochlorines is whether they are potent enough to result in abnormal changes such as those
demonstrated by both natural and synthetic estrogens. To test this hypothesis, female BALB/c
mice were treated neonatally (days 1-5) with either E2-17p or estradiol-17a (E2-17a), an inactive
stereoisomer in adult reproductive tissues. We also proposed whether neonatal administration of
(E2-17a) was tumorigenic and whether the effects were age dependent. To answer these
questions, one set each of 10-day-old treated and control mice received short-term secondary
administration of E2-170, E2-17a, or cholesterol. Cervicovaginal tracts from intact BALB/c mice
were examined histologically and by flow cytometry at 70 days of age and by histology alone at 18
to 22 months of age. The results include several important findings: a) like E2-17p, neonatal E2-17a
treatment induced persistent vaginal cornification, hypospadias, vaginal concretions, and
hyperproliferation in nearly 100% of the animals regardless of the secondary treatment for most
groups; b) neonatal E2-177a treatment increased the nuclear DNA content of cervicovaginal
epithelium at one-half both the level (mean DNA index of 1.02 vs 1.04) and incidence (22 vs 46%
of the animals) of E2-170; c) short-term secondary treatment with E2-17a, unlike E2-170, did not
significantly augment the increase in DNA content (13% for E2-17a vs 37 and 56% for control and
E2-171, respectively); and d) neonatal administration with E2-17a induced adenosquamous tumors
in the reproductive tract in 25% of the animals. Therefore, the biological effects (estrogenic potency)
of E217a may be age dependent. Environ Health Perspect105(Suppl 3):577-581 (1997)
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Introduction
Natural and synthetic estrogens are extensively to study both the etiology and
carcinogenic in humans and rodents (1-3). potential danger of in utero steroid expo-
In particular, the perinatal mouse treated sure to induce morphological, develop-
with sex steroid hormones has been used mental, biochemical, and carcinogenic
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changes in the human reproductive tract
(1,3-5). Neonatal treatment offemale mice
with 17p-estradiol (E2-17p) results in per-
manent, irreversible morphological andbio-
chemical changes in the cervicovaginal
(CV) epithelium including hyperplastic
proliferation ofthe epithelium with exten-
sive cornification and downgrowths
followed by subsequent neoplastic develop-
ment (3). We have previously demon-
strated that increased nuclear DNAcontent
in the CV epithelium precedes neoplastic
development in neonatally E2-17[3-treated
mice (6). The latency period for the
appearance ofthis change in DNA ploidy
can be shortened from 8 months to 40 days
with secondaryE2-17P administration (6).
Several studies concentrating on
estrogens, both in vitro and in vivo, have
hypothesized that genotoxic effects (7-9),
altered gene expression (10), and catechol
metabolites of estrogen (5,11-13) are
examples of the potential mechanisms of
estrogen-induced carcinogenesis. The role
ofestrogen and its receptor is better under-
stood in promotion; it is unclearwhat role,
if any, the receptor plays in estrogen-
induced carcinogenesis (3,5,14,15). Several
studies have demonstrated that the estro-
genic potency ofa compound alone is a
poor predictor ofits carcinogenic potential
(14,16,17). In contrast, weak. estrogenic
compounds as well as antiestrogenic com-
pounds, as determined by assays using
postnatal tissues, have induced changes
similar to those induced byE2-17IP in the
neonatal mouse (1,3-5,13,14).
The present studies were undertaken to
determine ifa weak estrogen administered
during a critical period ofdevelopment
results in an increase in the nudear DNA
content in the CVepithelium. Specifically,
the early effects of neonatal treatment
with the weakly estrogenic stereoisomer of
E2-17fS, estradiol-17a (E2-170), were
compared to the early E2-17p-induced
effects by both histological and flow cyto-
metric analysis. To determine whether the
effects of E2-17a were age dependent,
animals were treated secondarily with -
E2-17a, E2-17P, or cholesterol and com-
pared. The ultimate tumorigenicity of
E2-17a was also investigated.
Materials and Methods
Chemical
All chemicals and reagents were of the
highest grade commercially available. The
Environmental Health Perspectives - Vol 105, Supplement 3 * April 1997
..l I...
577HAJEK ETAL.
E2-17a (Steraloids, Wilton, NH) was
purified by recrystallization 4 times; each
recrystallization was performed using dif-
ferent solvent combinations than previous
ones (18). The steroid was subsequently
desiccated before weighing.
Animals andTreatment
Animal care was in accordance with
institutional guidelines. Seventy-two new-
born female BALB/c mice (Harlan Sprague
Dawley, Indianapolis, IN) were separated
into nine groups (Table 1). In accordance
with previously described procedures for
this model, the mice received daily sc injec-
tions of 25 mg of either E2-17J0 (Sigma
Chemical Co., St. Louis, MO) or E2-17a
in 0.02 ml ofvehicle (sesame oil), orvehicle
alone for 5 days, beginning within 15 hr of
birth (3). One set each of 10-day-old E2-
17,-treated, E2-17a-treated, and control
mice received sc pellet implants containing
either 15 mg ofE2-17P and cholesterol
(10:90, respectively), 15 mg ofE2-17a and
cholesterol (10:90, respectively), or 25 mg
ofcholesterol alone. A continuous release of
hormone is assured for up to 12 weeks UG
Liehr, personal communication). All mice
were weaned at 21 days ofage. Persistent
cornification was based on the vaginal
smears performed from days 20 to 30. The
CV tracts were analyzed at 70 days ofage
following 60 days ofsecondary treatment.
This time point was chosen on the basis of
previous studies that demonstrated the
reduced latency period for detecting
increased DNA content in the CV epithe-
lium (6). The CV tracts were analyzed at
18 to 22 months of age in an additional
three groups ofanimals.
TssuePreparation andDispersion
After removal, CV tracts were cut in half
longitudinally. One-half ofeach tract was
analyzed histologically; the other halfwas
enzymatically and mechanically dispersed
as previously described (6). This method
results in a cell suspension consisting of
more than 85% epithelial cells as determined
by identification with antibodies against
keratins (LAJones, unpublished data).
FlowCytometricAnalysis
The nuclear DNA content ofthe dispersed
CV epithelial cells was analyzed using a
Becton-Dickinson FACScan flow cytome-
ter (Becton-Dickinson, San Jose, CA)
under conditions previously described (6).
Normal BALB/c mouse lymphocytes
stained under the same conditions were
used as an internal diploid standard.
Lymphocytes were run before and after each
five unknown samples. Data were rejected if
the modal channel of the lymphocytes
varied by2% or more at any time.
Flow cytometric data were obtained
with Lysis II software (Becton-Dickinson).
The DNA index (DI) ofeach sample was
compared with the DI ofthe lymphocytes
and was subsequently used to compare the
samples statistically.
Histology
The other halves of the CV tracts were
snap frozen in liquid N2. The tissue sam-
ples were embedded in Tissue Tek OCT
compound (Miles Diagnostic Division,
Elkhart, IN). Four-micrometer sections
were cut with a cryostat and placed on
poly-L-lysine-coated slides. The slides were
dried for 30 min at 60°C and stained with
hematoxylin and eosin, and periodic
acid-Schiff(PAS) without digestion.
The following parameters were used to
evaluate the serial histological sections for
CV abnormalities: hyperproliferation, kera-
tinization, mild to severe dysplasia and
downgrowths, and pyknosis. The presence
of these parameters were scored in 10
random fields ofview (x20). To control for
animal variation within the groups, a mean
histologic score was calculated for each para-
meter for each animal using the histological
data from the 10 random fields ofview.
This mean histologic score, equal to the
total number ofoccurrences for each para-
meter divided by 10, was used to statistically
compare frequency rather than incidence.
StatisticalAnalysis
A Fisher exact test was used to compare the
incidence between groups for the gross
morphologic, histologic, and flow cytomet-
ric data. Using the mean histologic scores, a
range test based on a Kruskal-Wallis (K-W)
two-way analysis ofvariance (ANOVA)
was used to compare the frequency of the
histological parameters nonparametrically.
A range test based on a K-W two-way
ANOVA with multiple comparison tests
was used to test nonparametrically for dif-
ferences in nuclear DNA content between
groups. The factors analyzed were type of
initial treatment [(INIT) E2-17P, E2-17a,
or oil] and type of secondary treatment
[(SCND) E2-17P, E2-17a, cholesterol].
Differences between two groups were con-
sidered to be significant when the p value
was < 0.05. (All statistics were calculated
with SPSS, Chicago, IL).
Results
EarlyHistologca Effec
ofNeonatalTreatment
Neonatal treatment with E2-17a induced
premature vaginal opening, persistent
cornification, clitoroidal hypospadias, and
concretions in the vaginal lumen equiva-
lent to the incidence observed in the E2-
17p-treated animals (Table 1). Gross
morphological changes in the entire genital
Table 1. Incidence ofabnormalities in the cervicovaginal tract of mice treated neonatally with estrogen.
No. animals/ Abnormality, no. (%)
Treatmenta group PVOb Concretionsc Hypospadiasd pVCe HYPf Dl>1.05 Mean DI
Oil/CH 6 0 01,g 0 0 0 01.g 1.001
Oil/l17a 8 0 og 0 o a ° ,g 1.0110
Oil/17,B 8 0 01.g 0 0 8(100) 01,g 1.0010
17a/CH 10 10(100) 9(90)3,g 9(90) 10(100) 10(100) 3(30)12.g 1.031-3,h
l7a/17a 6 6(100) 3(50)1-3,g 6(100) 6(100) 6(100) 1 (17)1 9 1.021,2,h
17a/170 6 6(100) 4(66)2,3.g 5(83) 6(100) 6(100) 1 (17)19 1.021-3,h
17J/CH 9 9(100) 8(89)3.g 9(100) 9(100) 9(100) 4(44)1-2,g 1.052,3,h
17p/17a 9 9(100) 3(33)1,2,g 8(89) 9(100) 9(100) 1 (11)1g9 .021,2,h
17i/17,B 10 10(100) 7(70)2,3,g 9(90) 10(100) 10(100) 8(80)2,3,g 1.073,h
Abbreviations: 17a, 17at-estradiol; 17J, 17p-estradiol. CH, cholesterol; HYP, hyperproliferation; PVC, persistentvaginal cornification; PVO, prematurevaginal opening. 8lnitial
neonatal treatment/secondary treatment. bPVO before day 10. cConcretions found either before or at the time of sacrifice. dClitoroidal hypospadias, determined at time of
sacrifice. ePVC based on vaginal smears performed on days 30 to 40. fHYP 2 10 epithelial cell layers. UValues with different superscript numbers are significantly different
using the Fisher exacttest(p<0.05). 1Values with different superscript numbers aresignificantlydifferentusing a range testbased on a K-Wtwo-wayANOVA(p<0.05).
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tract, characteristic ofE2-17P treatment,
were also seen in all the E2-17ct-treated
animals (Figure 1). Neonatal treatment
with E2-17a induced hyperproliferation
and mild dysplasia and downgrowths in
the CV tract indistinguishable from those
changes described by Takasugi and Bern
(3) and seen in the E2-17p-treated ani-
mals. No significant histological difference
was observed between the two treated
groups in either the incidence/animal and
the prevalence/animal for hyperplasia,
dysplasia, and pyknosis. A significant rela-
tionship existed between the presence of
pyknosis and the presence ofmild to severe
dysplasia (p<0.01). With the exception of
secondary administration ofE2-17P induc-
ing hyperproliferation in the oil-treated
animals, secondary administration ofeither
E2-17P or E2-17a did not significantly
alter the histological changes.
FlowCytometicAnalysis
As shown in Table 2, the incidence of
significantly increased DI (DI > 1.05) was
significantly higher in the neonatally estro-
gen-treated animals when compared to
controls. Several E2-17a-treated animals
also possessed an increased DI (Figure 2)
but at a lower level and incidence. As
shown in Table 3, a higher mean DI and a
significantly increased incidence was
observed with subsequent short-term sec-
ondary E2-17p administration (p<0.01).
In contrast, secondary E2-177a administra-
tion did not significantly alter the DI of
any animals. The main effects in the two-
way ANOVA (INIT, SCND) were both
significant at p<0.001. The second-order
interaction (INITxSCND) was also sig-
nificant atp<0.007.
Tumorgenicity
Two of the eight E2-177a-treated animals
sacrificed between 18 and 24 months of
age developed tumors. Both tumors were
classified as adenosquamous (Figure 3). In
addition, areas having the potential to
eventually become tumors were found in
two additional animals. The incidence of
tumor formation in these studies was sig-
nificantly increased (p <0.001) over that
expected for controls [1:5000 (LA Jones,
unpublished data)] and approximately one-
halfof that expected for an equal dose of
E2-17P (Table 4).
Discussion
This study demonstrated that neonatal
treatment with E2-177a can induce terato-
genic and morphological changes equivalent
Figure 1. Comparison of 70-day-old reproductive tracts
from a normal neonatal oil-treated animal (A) and a
neonatal E2-17a-treated animal (B). Both animals were
treated secondarily with cholesterol for 60 days. Note
the increased size of the uterus, cervix, and vagina in
the estrogen-treated animal. Also note the normal
presence of the urethra (arrows) in the oil-treated ani-
mal and the absence of a urethra in the estrogen-
treated animal. Subsequent histological analysis
confirmed the presence of clitoroidal hypospadias in
the estrogen-treated animal.
Table 2. Incidence and degree of DNA ploidy changes
based on neonatal treatment.
Number ofanimals Mean
Treatmenta Pergroup With Dl >1.05% Dl
Oil 22 0 (0)1,b 1.00
17P-E2 28 13 (46)2.b 1.04
17a-E2 22 5 (22)2,b 1.02
aInitial neonatal treatment on days 1 to 5 with daily sc
injections. bValues with different superscript numbers
are significantly different using the Fisher exact test
(P<0.05).
to those induced by neonatal treatment
with E2-17f3 in the CV tract. Even though
neonatal administration with E2-17ct is
tumorigenic, the incidence may be lower
than with E2-17P. Furthermore, the
increased nuclear DNA content suggests
that neonatal treatment with E2-17ct
induces potential neoplastic conditions in
the CV epithelium (6) and that these
changes play a role in the subsequent tumor
formation. Our findings are in agreement
with those ofForsberg and Kalland (19),
who described the presence ofheterotropic
columnar epithelium in an outbred strain
following neonatal treatment with E2-17a.
The additional abnormalities described in
the present study, particularly the increased
DNA ploidy and tumorigenesis, indicate
that the estrogenic potency ofa compound
may be increased in neonatal tissues, as
evidenced by the inability of secondary
E2-17a administration to augment the
0)
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Figure 2. Representative relative nuclear DNA content
histograms. (A) Comparison between diploid mouse
lymphocytes and (B) 70-day-old neonatally E2-17a-
treated cervicovaginal epithelium after secondary cho-
lesterol administration for 60 days for(A) and (B) were
1.00 and 1.11, respectively.
Table 3. Incidence and degree of DNA ploidy changes
based on secondary treatment without neonatal oil-
treated animals.
Numberofanimals Mean
Treatmenta Pergroup With Dl .1.05(%) Dl
Cholesterol 19 7 (37)1.b 1.04
170-E2 16 9 (56)2.b 1.05
17a-E2 15 2 (13)1.b 1.01
"Secondary treatment from days 10 to 70, with sc pel-
let implants. hValues with different superscript num-
bers are significantly different using the Fisher exact
test(p<0.05).
increased DNA ploidy. Many studies in a
variety ofsystems have demonstrated that
E2-17a is a weak or inactive estrogen. For
example, a significantly lower relative bind-
ing affinity for the estrogen receptor in
both human endometrium and rat uterus
and a corresponding potency of6% were
observed when compared to E2-17P (20).
The potency ofE2-17a in stimulating cell
growth and prolactin production was
approximately 100-fold lower and the
binding affinity was 10-fold lower in rat
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Figure 3. Photomicrographs of hematoxylin and eosin staining illustrating an adenosquamous tumor induced by
neonatal E2-17cx administration in the CV tract from a 24-month-old animal that received no further treatment. (A)
Note the squamous components (arrow [x63]). (B) Also note the glandular components (arrow [x500]).
pituitary cells than the potency ofE2-17P
(21). Even though the binding for type I
estrogen receptor sites by E2-177a is dimin-
ished, it is unable to compete for type II
sites (22). The induction of gene expres-
sion such as c-fos in rat uterus and guinea
pig endometrium is specific for E2-17P
(23,24). On the other hand, several studies
have demonstrated similar effects between
the two stereoisomers such as growth inhi-
bition ofMCF-7 cells (25). Furthermore,
although strain differences have been
documented, it is unclear whether the
epithelial cells in the CV tract of BALB/c
mice possess estrogen receptors on days 1
to 3 after birth (26). Likewise, it is not
clear whether these effects are receptor
mediated. The role of primitive nondis-
criminatory receptors, orphan receptors, or
the mesenchyme cannot be discounted
(5,13-15,19). Other possible nongenomic
mechanisms of action for E2-17a include
conversion to E2-17P (27), common reac-
tive metabolites with E2-17P (5,11-13),
Table 4. Relative tumorgenicitycomparison.
Numberofanimals
Treatmenta Pergroup With tumors (%)
Oil -5000 1 (0.0002)b
17P-E2 -5000 -2500 (50)b
17a-E2 8 2 (8)c
"Initial neonatal treatment on days 1 to 5 with daily sc
injections of either 25 pg of steriod in vehicle (sesame
oil) or vehicle alone.bApproximation of combined
results over the past 20 years.cActual values obtained
during this current investigation.
aneuploidy (5,7-9), and the rapid release
ofintracellular calcium (28). Conversion
of E2-17a to E2-17f and/or prolonged
administration ofE2-17a was proposed by
Clark and associates (27), who observed a
uterotropic effect in mature rats. Unlike
E2-17f, chronic treatment with E2-17a
did not induce Leydig cell hyperplasia in
BALB/c mice (29). It is unclear which
mechanism(s) is playing a role in the
changes observed in this study.
More important, these results strengthen
the concerns put forth by McLachlan and
colleagues that weak environmental estro-
genic compounds, as judged by assays
using postnatal tissues, may have dramatic
potent estrogenic effects in developing
perinatal tissues (1,4,5,13,30). These peri-
natal estrogenic effects include functional,
teratogenic, and carcinogenic changes in
hormone-target tissues. In the present
study, the potency of E2-17a was age
dependent in that the effects observed were
significant and similar to those observed
forE2-170 when E2-17a was administered
neonatally, including tumorigenesis. In
contrast, the potency and effects resulting
from secondary treatment ofE2-17a were
not like those ofE2-170. Findings result-
ing from the neonatal mouse model may
apply to other hormone-sensitive tissues,
particularly during development, and may
provide predictors for hormonal carcino-
genesis (4). For example, only one out of
three breast cancer patients has an identifi-
able risk factor. While some investigators
have implicated the exposure to high con-
centrations ofendogenous prenatal estro-
gen in the development ofbreast cancer
(31), it may also be suggested that exposure
to weak environmental estrogens during a
critical period ofdevelopment may also play
a role (1,4,5,13,32,33). Further studies are
both under way and needed to further
define the mechanism ofaction ofestrogen-
and steroid-induced carcinogenesis in
this model.
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